# Treatment diversification is an essential strategy for mitigating antimicrobial resistance

**Authors:** Lao-Tzu Allan-Blitz, Jeffrey D Klausner

PMC · DOI: 10.1093/haschl/qxaf032 · Health Affairs Scholar · 2025-03-10

## Full-text entities

- **Diseases:** infections (MESH:D007239), Allergy and Infectious Diseases (MESH:D003141)
- **Chemicals:** macrolide (MESH:D018942), methicillin (MESH:D008712), ciprofloxacin (MESH:D002939), clarithromycin (MESH:D017291), levofloxacin (MESH:D064704), ceftriaxone (MESH:D002443)
- **Species:** Neisseria gonorrhoeae (species) [taxon 485], Staphylococcus aureus (species) [taxon 1280], Helicobacter pylori (species) [taxon 210], Mycoplasmoides genitalium (species) [taxon 2097]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11890987/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC11890987/full.md

---
Source: https://tomesphere.com/paper/PMC11890987